Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01882764 · ClinicalTrials.gov registry record · Phase 3

HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis

A Phase 3 study, sponsored by Hutchison Medipharma Limited.

Terminated
Registry status
Phase 3
Development phase
66
Enrollment target

NCT01882764 is a Phase 3 study that was terminated before completion, run by Hutchison Medipharma Limited. The registered enrollment target is 66 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01882764, a Phase 3 study, was terminated before completion, sponsored by Hutchison Medipharma Limited.

TERMINATED
Registry status
Phase 3
Development phase
66 participants
Enrollment target

Study Summary

A study with an 8 week open label phase study followed by a year long placebo controlled maintenance phase in subjects with active mild to moderate ulcerative colitis (UC), with a modified Mayo Score 4-10 and an endoscopy subscore of 2-3, taking mesalamine (or equivalent) as a concomitant medication. Subjects are required to be in clinical remission or clinical response to enter the year long maintenance phase. This study will help evaluate if HMPL-004 is effective in subjects maintaining clinical remission following successful induction therapy achieving clinical remission or clinical response.

Interventions

  • DRUG Placebo
  • DRUG HMPL-004

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2013-06
Est. Completion 2014-10
Phase Phase 3

Sponsor

Hutchison Medipharma Limited

11 total trials

What the Registry Record Tells You About NCT01882764

The ClinicalTrials.gov registry entry for NCT01882764 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hutchison Medipharma Limited, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01882764 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01882764 about?

NCT01882764 is a clinical study titled "HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis". A study with an 8 week open label phase study followed by a year long placebo controlled maintenance phase in subjects with active mild to moderate ulcerative colitis (UC), with a modified Mayo Score 4-10 and an endoscopy subscore of 2-3, taking mesalamine (or equivalent) as a concomitant medication...

What is the current status of trial NCT01882764?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 66 participants. The study started on 2013-06. Estimated completion is 2014-10.

What interventions are being tested in trial NCT01882764?

The interventions under investigation include: Placebo (DRUG), HMPL-004 (DRUG).

Who is sponsoring clinical trial NCT01882764?

This trial is sponsored by Hutchison Medipharma Limited, which has 11 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.